


## Zacopride hydrochloride

<b>Cat. No.:</b>	HY-103137
<b>CAS No.:</b>	101303-98-4
<b>Molecular Formula:</b>	C <sub>15</sub> H <sub>21</sub> Cl <sub>2</sub> N <sub>3</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	346.25
<b>Target:</b>	5-HT Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



H-Cl

### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (288.81 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	<b>Preparing Stock Solutions</b>		1 mg	5 mg	10 mg
		1 mM	2.8881 mL	14.4404 mL	28.8809 mL
		5 mM	0.5776 mL	2.8881 mL	5.7762 mL
	10 mM	0.2888 mL	1.4440 mL	2.8881 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (7.22 mM); Suspended solution; Need ultrasonic				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Zacopride hydrochloride is a highly potent 5-HT <sub>3</sub> receptor antagonist with K <sub>i</sub> s of 0.38 and 373 nM for 5-HT <sub>3</sub> and 5-HT <sub>4</sub> receptor, respectively. Zacopride hydrochloride is also a moderate I <sub>K1</sub> channel agonist. Zacopride hydrochloride exerts significant antiarrhythmic and cardiac protective effects <sup>[1][2][3]</sup> .
--------------------	---

### REFERENCES

[1]. Nagakura Y, et al. Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5-HT<sub>4</sub> receptor versus human 5-HT<sub>3</sub> receptor. Pharmacol Res. 1999;39(5):375-382.

---

[2]. Costall B, et al. Zacopride: anxiolytic profile in rodent and primate models of anxiety. *J Pharm Pharmacol*. 1988;40(4):302-305.

[3]. Newcomer JW, et al. Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial. *Arch Gen Psychiatry*. 1992;49(9):751-752.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA